The Lancet Haematology

1. EHA 2021 Virtual Congress

   Publication date: Available online 18 June 2021

   Source: The Lancet Haematology

   Author(s): Owen Stretton

2. Eliminating race-based reference ranges in haematology: a call to action

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s): Angela C Weyand, Patrick T McGann

3. CAR T-cell therapy for multiple myeloma: state of the art and prospects

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s): Niels W C J van de Donk, Saad Z Usmani, Kwee Yong

4. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s): Mehdi Hamadani, Graham P Collins, Paolo F Caimi, Felipe Samaniego, Alexander Spira, Andrew Davies, John Radford, Tobias Menne, Anand Karnad, Jasmine M Zain, Paul Fields, Karin Havenith, Hans G Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, Steven Horwitz

5. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s): Benjamin Diamond, Neha Korde, Alexander M Lesokhin, Eric L Smith, Urvi Shah, Sham Mailankody, Malin Hultcrantz, Hani Hassoun, Sydney X Lu, Carlyn Tan, Even H Rustad, Francesco Maura, Kylee Maclachlan, Tim Peterson, Andriy Derkach, Sean Devlin, Heather J Landau, Michael Scordo, David J Chung, Gunjan L Shah

6. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s): David J Straus, Monika Długosz-Danecka, Joseph M Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J Savage, Nancy L Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Munoz, Hun Ju Lee, Won Seog Kim, Ranjana Advani, Stephen M Ansell

7. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s): Stefanie Kreissl, Helen Goergen, Ina Buehnen, Carsten Kobe, Alden Moccia, Richard Greil, Dennis A Eichenauer, Josée M Zijlstra, Jana Markova, Julia Meissner, Michaela Feuring-Buske, Martin Soekler, Hans-Joachim Beck, Wolfgang Willenbacher, Wolf-Dieter Ludwig, Thomas Pabst, Max S Topp, Felicitas Hitz, Martin Bentz, Ulrich Bernd Keller

8. Correction to Lancet Haematol 2021; 8: e205–15

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s):

9. Correction to Lancet Haematol 2021; 8: e185–93

   Publication date: June 2021

   Source: The Lancet Haematology, Volume 8, Issue 6

   Author(s):

10. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

    Publication date: June 2021

    Source: The Lancet Haematology, Volume 8, Issue 6

    Author(s): Sarah Bird, Aikaterini Panopoulou, Robyn L Shea, Micky Tsui, Radovan Saso, Amit Sud, Sharon West, Katy Smith, John Barwood, Ewa Kaczmarek, Carmela Panlaqui, Martin Kaiser, Simon Stern, Charlotte Pawlyn, Kevin Boyd

11. Anti-CD25 antibody–drug conjugates: improving the delivery of death to lymphoma cells?

    Publication date: June 2021

    Source: The Lancet Haematology, Volume 8, Issue 6

    Author(s): Norbert Schmitz, Georg Lenz

12. Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy

    Publication date: June 2021

    Source: The Lancet Haematology, Volume 8, Issue 6

    Author(s): Susan Bal, Luciano J Costa

13. A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma

    Publication date: June 2021

    Source: The Lancet Haematology, Volume 8, Issue 6

    Author(s): Louis F Diehl

14. Bleeding disorders: adapting to change

    Publication date: June 2021

    Source: The Lancet Haematology, Volume 8, Issue 6

    Author(s): The Lancet Haematology

15. Ocular involvement in extranodal natural-killer T-cell lymphoma

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Peizeng Yang, Zhenyu Zhong, Zi Ye, Jia Shu

16. The power of specialty palliative care: moving towards a systems perspective

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Amber E Barnato, Inas S Khayal

17. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Eric J Zhao, Catherine V Cheng, Andre Mattman, Luke Y C Chen

18. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Élie Azoulay, Pedro Castro, Adel Maamar, Victoria Metaxa, Alice Gallo de Moraes, Louis Voigt, Florent Wallet, Kada Klouche, Muriel Picard, Anne-Sophie Moreau, Andry Van De Louw, Amélie Seguin, Djamel Mokart, Sanjay Chawla, Julien Leroy, Boris Böll, Nahema Issa, Bruno Levy, Pleun Hemelaar, Sara Fernandez

19. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Antonio M Risitano, Alexander Röth, Juliette Soret, Camilla Frieri, Flore Sicre de Fontbrune, Luana Marano, Ferras Alashkar, Lina Benajiba, Serena Marotta, Izabela Rozenberg, Julie Milojevic, Peter End, Prasanna K Nidamarthy, Guido Junge, Régis Peffault de Latour

20. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Bart J Biemond, Anil Tombak, Yurdanur Kilinc, Murtadha Al-Khabori, Miguel Abboud, Mohammed Nafea, Adlette Inati, Yasser Wali, Jens Kristensen, Jan Kowalski, Ellen Donnelly, John Ohd, Erfan Nur, Anita W. Rijneveld, Alibülent Antmen, Marvin Reid, Gabriel Ukala, Lisa Kirven-Dawes, Curis Yeates, Hugh Wong

21. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Jo Howard, Kenneth I Ataga, Robert C Brown, Maureen Achebe, Videlis Nduba, Amal El-Beshlawy, Hoda Hassab, Irene Agodoa, Margaret Tonda, Sarah Gray, Joshua Lehrer-Graiwer, Elliott Vichinsky

22. 47th Annual Meeting of the EBMT

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Yaiza del Pozo Martín

23. Accurate accounting of caplacizumab cost effectiveness – Authors' reply

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Mary Hughes, Nicole Elliot, Amanda I Adler

24. Accurate accounting of caplacizumab cost effectiveness

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): George Goshua, Vinay Prasad, Alfred Ian Lee, Pavan K Bendapudi

25. COVID-19 vaccines for patients with haematological conditions

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Clare Sun, Christopher Pleyer, Adrian Wiestner

26. Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Janhavi Athale, Nirali N Shah

27. Factor B inhibition for paroxysmal nocturnal haemoglobinuria

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Robert A Brodsky

28. Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Patrick Ellsworth, Jane A Little

29. Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): Baba Psalm Duniya Inusa, Maddalena Casale, Andrew Campbell, Natasha Archer

30. COVID-19 vaccines: building and maintaining confidence

    Publication date: May 2021

    Source: The Lancet Haematology, Volume 8, Issue 5

    Author(s): The Lancet Haematology